Squarepoint Ops LLC Acquires 50,924 Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL)

Squarepoint Ops LLC raised its position in shares of Anavex Life Sciences Corp. (NASDAQ:AVXL - Free Report) by 304.9% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 67,627 shares of the biotechnology company's stock after purchasing an additional 50,924 shares during the quarter. Squarepoint Ops LLC owned 0.08% of Anavex Life Sciences worth $726,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in AVXL. China Universal Asset Management Co. Ltd. lifted its stake in shares of Anavex Life Sciences by 10.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 17,980 shares of the biotechnology company's stock worth $193,000 after purchasing an additional 1,671 shares during the period. Tower Research Capital LLC TRC increased its holdings in Anavex Life Sciences by 102.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 3,383 shares of the biotechnology company's stock valued at $36,000 after buying an additional 1,708 shares during the last quarter. Opus Capital Group LLC raised its position in Anavex Life Sciences by 6.1% in the fourth quarter. Opus Capital Group LLC now owns 34,700 shares of the biotechnology company's stock worth $373,000 after acquiring an additional 2,000 shares during the period. Nwam LLC raised its position in Anavex Life Sciences by 0.3% in the fourth quarter. Nwam LLC now owns 913,051 shares of the biotechnology company's stock worth $9,806,000 after acquiring an additional 2,575 shares during the period. Finally, Ameriprise Financial Inc. boosted its stake in shares of Anavex Life Sciences by 5.1% during the 4th quarter. Ameriprise Financial Inc. now owns 66,810 shares of the biotechnology company's stock worth $718,000 after acquiring an additional 3,243 shares during the last quarter. 31.55% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

AVXL has been the subject of several analyst reports. D. Boral Capital restated a "buy" rating and issued a $46.00 price objective on shares of Anavex Life Sciences in a research note on Monday, April 7th. HC Wainwright reissued a "buy" rating and set a $42.00 price target on shares of Anavex Life Sciences in a report on Monday, April 7th.

Anavex Life Sciences Trading Up 6.3%

Anavex Life Sciences stock traded up $0.49 during midday trading on Friday, hitting $8.27. The stock had a trading volume of 1,187,633 shares, compared to its average volume of 1,218,316. The firm's fifty day moving average is $8.43 and its two-hundred day moving average is $9.08. The company has a market capitalization of $706.03 million, a PE ratio of -15.04 and a beta of 0.82. Anavex Life Sciences Corp. has a 52-week low of $3.51 and a 52-week high of $14.44.

Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) last posted its quarterly earnings results on Tuesday, May 13th. The biotechnology company reported ($0.13) earnings per share for the quarter, topping analysts' consensus estimates of ($0.16) by $0.03. During the same quarter in the prior year, the business earned ($0.13) earnings per share. As a group, equities research analysts predict that Anavex Life Sciences Corp. will post -0.69 earnings per share for the current fiscal year.

About Anavex Life Sciences

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.